Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.48 |
| ▸ | MARK3 | P27448 | 2/20 | 0.48 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14112812 | 0.93 | TBK1 (0.51) | SYKTBK1MARK3MARK4AURKA | |
| SCHEMBL13897769 | 0.88 | SYK (0.51) | SYKTBK1MARK3MARK4AURKA | |
| SCHEMBL3866461 | 0.88 | AURKA (0.47) | SYKTBK1MARK3MARK4AURKA | |
| SCHEMBL3867648 | 0.88 | IGF1R (0.52) | SYKMAPK8TBK1MARK3MARK4 | |
| SCHEMBL13897933 | 0.87 | TBK1 (0.49) | SYKMAPK8TBK1MARK3MARK4 | |
| SCHEMBL13897771 | 0.86 | MARK3 (0.51) | SYKTBK1MARK3MARK4AURKA | |
| SCHEMBL3958041 | 0.86 | CDK19 (0.57) | SYKTBK1MARK3MARK4AURKA | |
| SCHEMBL13897853 | 0.86 | TBK1 (0.55) | SYKTBK1MARK3MARK4AURKA | |
| SCHEMBL3866798 | 0.86 | TBK1 (0.55) | SYKTBK1MARK3MARK4AURKA | |
| SCHEMBL13897910 | 0.86 | TBK1 (0.55) | SYKMAPK8TBK1MARK3MARK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | claimed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | SYK 1402/4885MAPK8 325/4885TBK1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.